Latest Breaking News On - Deka biosciences - Page 3 : comparemela.com

Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)

Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPrnewswire deka biosciencesJohn mummDeka biosciencesClinical director

Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application

/PRNewswire/ Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today.

United statesJohn mummPrnewswire deka biosciencesDrug administrationDeka biosciencesHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesFda approvalNew products amp services

In a historic year for VC investment, Baltimore shattered recent records to raise $768M

Both the region and state saw major VC activity this year, according to the 2021 PitchBook-NVCA Venture Monitor. By the third quarter, 2021 had already soared past 2020's record. Q4 was just icing on the cake.

United statesJohn gabbertDeka biosciencesBobby franklinRobotic researchSilicon valley bankNational venture capital associationVheda healthNovel microdevicesRasio therapeuticsPresident bobby franklin

Montgomery County leading in advances in bio health innovation around Md

If there is an industry for which Maryland is best known these days, it might just be bio health.

United statesNational institutes of healthUniversity of marylandNorth bethesdaFrederick countyMontgomery countyUniversity of maryland school medicineMark elrichJohn mummMary kaneMarkt gladwinDeka biosciencesPavel khrimianUs department of agricultureMontgomery county councilUniversity of maryland baltimore

Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)

/PRNewswire/ Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory.

John mummDeka biosciencesDeka biosciences incDrug administrationImportant regulatory milestone provides runwayInvestigational new drugHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesNew products amp services